Champions Oncology Stock Forecast, Price & News

Wall Street analysts have given Champions Oncology a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Champions Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Champions Oncology is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Champions Oncology.

Champions Oncology, Inc. (NASDAQ:CSBR) released its quarterly earnings results on Monday, December, 14th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of $0.01. The biotechnology company earned $10.12 million during the quarter, compared to the consensus estimate of $9.63 million. Champions Oncology had a negative trailing twelve-month return on equity of 29.93% and a negative net margin of 4.18%.
View Champions Oncology's earnings history.

Champions Oncology's stock was trading at $4.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CSBR shares have increased by 135.8% and is now trading at $11.72.
View which stocks have been most impacted by COVID-19.

Champions Oncology issued an update on its FY 2021 After-Hours earnings guidance on Monday, December, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $38.548-40.154 million, compared to the consensus revenue estimate of $38.56 million.

8 employees have rated Champions Oncology CEO Ronnie Morris on Glassdoor.com. Ronnie Morris has an approval rating of 50% among Champions Oncology's employees. This puts Ronnie Morris in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Champions Oncology include Athira Pharma (ATHA), Agenus (AGEN), Precision BioSciences (DTIL), DBV Technologies (DBVT), Jounce Therapeutics (JNCE), Solid Biosciences (SLDB), Compugen (CGEN), MeiraGTx (MGTX), Curis (CRIS), Oyster Point Pharma (OYST), Poseida Therapeutics (PSTX), Gritstone Oncology (GRTS), Fusion Pharmaceuticals (FUSN), Harpoon Therapeutics (HARP) and AVROBIO (AVRO).
View all of CSBR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Champions Oncology investors own include Gilead Sciences (GILD), Intel (INTC), Cytosorbents (CTSO), Micron Technology (MU), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), AbbVie (ABBV), Agile Therapeutics (AGRX), CRISPR Therapeutics (CRSP) and Exelixis (EXEL).

Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR."

Champions Oncology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.48%), Renaissance Technologies LLC (1.66%), Roubaix Capital LLC (1.54%), Millrace Asset Group Inc. (1.36%), Dimensional Fund Advisors LP (0.98%) and Northern Trust Corp (0.80%). Company insiders that own Champions Oncology stock include Daniel Newman Mendelson, Enterprise Associates 14 New, Philip P Breitfeld and Ronnie Morris.
View institutional ownership trends for Champions Oncology.

CSBR stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Globeflex Capital L P, Renaissance Technologies LLC, New York State Common Retirement Fund, Northern Trust Corp, Wells Fargo & Company MN, Charles Schwab Investment Management Inc., and Zebra Capital Management LLC. Company insiders that have sold Champions Oncology company stock in the last year include Enterprise Associates 14 New, Philip P Breitfeld, and Ronnie Morris.
View insider buying and selling activity for Champions Oncology or view top insider-selling stocks.

CSBR stock was bought by a variety of institutional investors in the last quarter, including Roubaix Capital LLC, Millrace Asset Group Inc., BlackRock Inc., and JPMorgan Chase & Co.. Company insiders that have bought Champions Oncology stock in the last two years include Daniel Newman Mendelson, and Ronnie Morris.
View insider buying and selling activity for Champions Oncology or or view top insider-buying stocks.

Shares of CSBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CSBR stock can currently be purchased for approximately $11.72.

Champions Oncology has a market capitalization of $156.68 million and generates $32.12 million in revenue each year. The biotechnology company earns $-1,980,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

Champions Oncology employs 143 workers across the globe.

The official website for Champions Oncology is www.championsoncology.com.

Champions Oncology is headquartered at One University Plaza Suite 307, Hackensack NJ, 07601.

Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected]